Karyopharm Therapeutics | KPTI - Selling And Administration Expenses


Karyopharm Therapeutics reported $9.56M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Abbott USD 3.27B 138M Mar/2026
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
J&J USD 6.03B 719M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Takeda JPY 292B 9.21B Mar/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
TG Therapeutics USD 73.14M 22.42M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Xencor USD 82.12M 65.08M Mar/2026